Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

Item Type:	Article
Title:	Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
Creators Name:	Baumgartner, F. and Baer, C. and Bamopoulos, S.A. and Ayoub, E. and Truger, M. and Meggendorfer, M. and Lenk, M. and Hoermann, G. and Hutter, S. and Müller, H. and Walter, W. and Mueller, M.L. and Nadarajah, Ni. and Blombery, P. and Keller, U. and Kern, W. and Haferlach, C. and Haferlach, T.
Abstract:	The World Health Organization Classification of Hematolymphoid Tumors (WHO) and the International Consensus Classification (ICC) of 2022 introduced major changes to the definition of CMML. To assess qualitative and quantitative implications for patient care, we started with 3,311 established CMML cases (according to WHO 2017 criteria) and included also 2,130 oligomonocytosis cases fulfilling the new CMML diagnostic criteria. Applying both classification systems from 2022, 356 and 241 of oligomonocytosis cases were newly classified as myelodysplastic (MD)-CMML (WHO and ICC 2022, respectively), most of which were diagnosed as MDS according to WHO 2017. Importantly, 1.5 times more oligomonocytosis cases were classified as CMML according to WHO 2022 than based on ICC, due to different diagnostic criteria. Genetic analyses of the newly classified CMML cases showed a distinct mutational profile with strong enrichment of MDS-typical alterations, resulting in a transcriptional subgroup separated from established MD- and myeloproliferative (MP)-CMML. Despite a different cytogenetic, molecular, immunophenotypic, and transcriptional landscape, no differences in overall survival were found between newly classified and established MD-CMML cases. To the best of our knowledge, this study represents the most comprehensive analysis of routine CMML cases to date, both in terms of clinical characterization and transcriptomic analysis, placing newly classified CMML cases on a disease continuum between MDS and previously established CMML.
Keywords:	Consensus, Chronic Myelomonocytic Leukemia, Leukocytosis, Myelodysplastic Syndromes, Organic Chemicals, Prognosis, World Health Organization
Source:	Blood
ISSN:	0006-4971
Publisher:	American Society of Hematology
Volume:	143
Number:	12
Page Range:	1139-1156
Date:	21 March 2024
Official Publication:	https://doi.org/10.1182/blood.2023021199
PubMed:	View item in PubMed

Repository Staff Only: item control page